Titles in action: GSK, Next, Stellantis

Here is a selection of announcements that have made (or will make) move the prices of these companies:

(Come back and read us from time to time
so as not to miss an update)

The British laboratory GSK (GSK.L, £ 1,391.20) and King’s College London on Friday announced a five-year research partnership to use artificial intelligence to better predict and personalize the impact of cancer treatments. The joint research hub will be formed by ten scientists from the King’s College Cancer Center and ten from GSK’s Artificial Intelligence and Experimental Medicine units. The aim is to understand “what role do genetic factors play” in the success of the treatment, “how and why some patients react to certain treatments and what may be at the origin of the progression of the disease in others”, according to a statement from King’s College. The pharmaceutical giant GSK (GlaxoSmithKline), which had presented mixed results at the end of July, between lower profit and recovery in sales, also hopes to launch at the end of 2021 a vaccine against COVID-19, developed by the French Sanofi, and has started Advanced phase 3 trials for another vaccine candidate with South Korean SK Bioscience.

The British clothing chain Next (NXT.L, £ 8,168) has entered into a joint venture agreement with US-based Gap to manage its UK and Ireland operations as a franchise partner, according to a joint statement on Friday. Next will own 51% of their joint venture – the remaining Gap – and manage digital businesses, outlets and online shopping services with collection across the region. The announcement comes after Gap’s July announcement of the closure of its 81 stores in Ireland and the UK as part of a “strategic review” of its operations in Europe. Gap also announced last October that it was considering closing its stores in France, the United Kingdom, Ireland and Italy. In France, on June 25, the Competition Authority approved the buyout by the FIB fund of the brand’s 21 French stores.

Carlos Tavares, general manager of the car manufacturer Stellantis (STLA.PA, £ 17.07), will be stepping down from the board of directors ofAirbus (AIR.PA, £ 113.30), Stellantis announced on Friday. “This personal decision will allow Carlos Tavares to devote all of his professional time to lead Stellantis to success, with his management team, in this period of transformation and evolution of the automotive industry,” the company explains in a press release. . The Portuguese administrator will leave the board of directors of the European aircraft manufacturer at the end of his second term in 2022. The boss of Stellantis, recently born from the merger of the French PSA with the Italian Fiat-Chrysler, had warned of ” enormous technological challenges ”that this new group would face in the era of the development of electric vehicles, digitization and autonomous driving. Stellantis, born in January 2021, brings together 14 iconic brands such as Citroën, Peugeot and Alfa Romeo. The goal of the PSA-Fiat Chrysler merger was to strengthen itself in particular against competitors Toyota and Volkswagen.



www.lesaffaires.com

Leave a Comment